Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table 2d. Nitazoxanide: Selected Clinical Data

Last Updated: July 8, 2021

The information in this table may include data from preprints or articles that have not been peer reviewed. This section will be updated as new information becomes available. Please see ClinicalTrials.gov for more information on clinical trials that are evaluating NTZ for the treatment of COVID-19. The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing recommendations for NTZ.1,2

Table 2d. Nitazoxanide: Selected Clinical Data
Table 2d. Nitazoxanide: Selected Clinical Data
  1. Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide in vitro efficacy against SARS CoV-2 and in vivo superiority to placebo to treat moderate COVID-19–a Phase 2 randomized double-blind clinical trial. Preprints with the Lancet. 2021. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3763773.
  2. Silva M, Espejo A, Pereyra ML, et al. Efficacy of nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. medRxiv. 2021;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.03.03.21252509v1.
  3. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33361100.
  4. Rossignol J, Bardin MC, Oaks JB, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv. 2021;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1.